Neural Analytics, Inc., a Los Angeles, CA-based medical device company developing and commercializing technology to measure, diagnose, and track brain health, raised $15m in Series B financing.
The round was led by Alpha Edison.
The company intends to use the funds to expand the team and to further advance the development of the Lucid System to assess and monitor additional brain health conditions.
Led by Leo Petrossian, Ph.D., Co-Founder and Chief Executive Officer, Neural Analytics provides The Lucid Transcranial Doppler Ultrasound System (Lucid System), which uses ultrasound to assess the brain’s blood vessels from outside the body. This analysis is non-invasive, can be performed in the physician’s office, and helps the physician diagnose brain disorders. The system is FDA-cleared and CE-marked for the monitoring of blood flow velocities in the cerebral vasculature. It is a battery-operated, medical-grade tablet device designed to be transported throughout a medical facility and in a range of clinical scenarios that require the rapid assessment of blood flow in the brain to expedite treatment.